← All trials
NCT04430842
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Sep 30, 2021
- Completion date
- Dec 31, 2021
- First posted
- Jun 12, 2020
- Last posted
- Jun 12, 2020
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Quadriga Biosciences, Inc.Lead sponsor
- NovotechCollaborator
Drugs studied
Indications studied
- Astrocytoma
- Urinary Bladder Neoplasms
- Brain Neoplasms
- Breast Neoplasms
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Head and Neck Neoplasms
- Kidney Neoplasms
- Liver Neoplasms
- Lung Neoplasms
- Melanoma
- Mesothelioma
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Prostatic Neoplasms
- Sarcoma
- Stomach Neoplasms
- Thymoma
- Tongue Neoplasms
- Urologic Neoplasms
- Colorectal Neoplasms
- Cholangiocarcinoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.